CIK 0001761612 · Non-accelerated filer<br>Smaller reporting company
BICYCLE THERAPEUTICS PLC
Sign in to watch- Ticker
- BCYC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- Phone
- 011441223261503
- Business address
- BLOCKS A & B, PORTWAY BUILDING, GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, United Kingdom, CB21 6GS
- Former names
- BICYCLE THERAPEUTICS Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $64,039
- in 7 filings, $7K under 10b5-1 plans
Net −$64,039. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Lee Kevin −$27K CHIEF EXECUTIVE OFFICER sold 1% of stake
- Swanton Robert Charles −$12K Director sold 18% of stake
- Skynner Michael −$9K CHIEF SCIENTIFIC OFFICER sold 2% of stake
- Perry Jennifer Scott −$7K Chief Operating Officer sold 2% of stake
- Hannay Michael Charles Ferguson −$6K CHIEF PROD & SUPPLY CHAIN OFF sold 2% of stake
Reading 60 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-04-28 | Lee Kevin Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | −22,495 | 462,576 | ||
| 2021-04-27 | Lee Kevin Chief Executive Officer | Option exercise | +6,636 | $14.00 | $93K | 261,370 |
| 2021-04-27 | Lee Kevin Chief Executive Officer | Sale | −6,278 | $30.66 | $192K | 255,092 |
| 2021-04-27 | Lee Kevin Chief Executive Officer | Sale | −358 | $31.41 | $11K | 254,734 |
| 2021-04-26 | Lee Kevin Chief Executive Officer | Option exercise | +14,545 | $14.00 | $204K | 273,345 |
| 2021-04-26 | Lee Kevin Chief Executive Officer | Sale | −4,715 | $30.63 | $144K | 268,630 |
| 2021-04-26 | Lee Kevin Chief Executive Officer | Sale | −13,896 | $31.50 | $438K | 254,734 |
| 2021-04-26 | Lee Kevin Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | −14,545 | 491,707 | ||
| 2021-04-26 | Lee Kevin Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | −6,636 | 485,071 | ||
| 2021-04-08 | Legault Pierre Director | Option exercise | +24,838 | $8.74 | $217K | 24,838 |
| 2021-04-08 | Legault Pierre Director | Sale | −12,500 | $32.00 | $400K | 12,338 |
| 2021-04-08 | Legault Pierre Director | Sale | −12,099 | $31.40 | $380K | 239 |
| 2021-04-08 | Legault Pierre Director | Sale | −239 | $32.13 | $8K | 0 |
| 2021-04-08 | Legault Pierre Director | Option exercise · Stock Option (Right to Buy) | −24,838 | 173,312 | ||
| 2021-04-05 | Legault Pierre Director | Option exercise | +162 | $8.83 | $1K | 162 |
| 2021-04-05 | Legault Pierre Director | Sale | −162 | $31.07 | $5K | 0 |
| 2021-04-05 | Legault Pierre Director | Option exercise · Stock Option (Right to Buy) | −162 | 198,150 | ||
| 2021-03-31 | Keen Nicholas Chief Scientific Officer | Sale | −10,000 | $30.00 | $300K | 28,321 |
| 2021-03-31 | Legault Pierre Director | Option exercise | +10,000 | $8.78 | $88K | 10,000 |
| 2021-03-31 | Legault Pierre Director | Sale | −10,000 | $30.00 | $300K | 0 |
Page 25 of 26 · 520 trades